Drug Profile
Minocycline topical - Hovione
Alternative Names: HY01; HY01 Topical GelLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Hovione
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rosacea
Highest Development Phases
- Phase II Rosacea
- No development reported Acne
Most Recent Events
- 29 Sep 2021 Minocycline topical - Hovione is available for licensing in World as of 29 Sep 2021. https://www.hovione.com/products-and-services/proprietary-product-licensing/proprietary-product-portfolio
- 29 Sep 2021 Minoclycline topical is still in phase II trials for rosacea in USA (Hovione pipeline, September 2021)
- 20 Sep 2019 Hovione has patent protection for minocycline topical gel worldwide